ABSTRACT
INTRODUCTION
Colorectal cancer is the third most common cancer and the second most common cause of cancer deaths in the United States where the vast majority of cases occurs over the age of 60 years
(1) . In Egypt, the relative frequency of cancer colon at the National cancer Institute, Cairo University from 2002 to 2007 was (3-5%)
(2) . The endogenous‚ β-galactosidebinding protein galectin-3 is a member of a family of carbohydratebinding proteins that have been implicated in cell growth, differentiation, adhesion, malignant transformation and apoptosis (3) . It also, plays a role in the metastasis of several carcinomas (4) . A study done by Iacovazzi et al., (5) showed that galectin-3 levels were higher in sera of non metastatic colorectal cancer patients than in controls, particularly in more differentiated tumors.
Matrix metalloproteinase 9 or gelatinase B is a member of matrix metalloproteinases family which is structurally related to zinc-dependent endopeptidases proteolytic enzymes that are collectively capable of degrading essentially all components of extracellular matrix (ECM) including the basement membrane and type IV collagen. They are associated with tissue remodeling in normal and pathological processes characterized by excessive degradation of ECM (6) , as rheumatoid arthritis, osteoarthritis, periodontitis, autoimmune blistering disorders of the skin, they also play a role in the development, invasion and metastasis Galectin-3, a 30-kDa chimera carbohydrate-binding protein is composed of three distinct structural motifs, an amino terminal domain consisting of 12 amino acid residues, preceding an amino terminal half of collagen-like sequence containing Pro-Gly-Tyr tandem repeats, and a sugar-binding carboxy terminal half (13) . The collagen-like domain of galectin-3 is susceptible to rapid and efficient cleavage by MMPs, in particular MMP-2, MMP-9, and membrane type 1-MMP resulting in the generation of a 22 kDa cleaved product (14) .
AIM OF WORK
To evaluate the role of galectin 3 and matrix metalloproteinase 9 in newly diagnosed colon cancer patients before treatment, and to compare their serum levels with the corresponding levels after treatment, with those of patient with benign colon lesion, and normal controls healthy subjects, Serum concentration of galectin 3 and matrix metalloproteinase 9 will also be compared with CEA, CA 19.9 and some prognostic factors of cancer colon. Table ( 1) shows the patients characteristics of the cancer colon patients Table ( 2) shows the patients characteristics of the after treatment cancer colon patients As regards, the benign colon patients, seven out of fifteen patients (46.6%) had tubular adenoma, 4/15 (26.6%) had hyperplasia, 1/15 (6.6%) had ulcerative colitis and 3/15 (20%) had inflammation.
PATIENTS & METHODS

RESULTS
Comparing serum level of CEA, CA19.9, galectin3 and MMP9 between the 4 studied groups revealed statistically significant difference (pvalue <0.0001 each).
Comparison the studied tumor markers between the different groups revealed statistically significant difference between each pair.
CEA was statistically significant for stage and lymph node metastasis and distant metastasis (p-value 0.0001, 0.0001 and 0.0026 respectively), CA19.9 was statistically significant for distant metastasis, stage and pathology (p-value <.0001, 0.0041 and 0.0043 respectively), galectin3 was statistically significant for distant metastasis (p-value 0.0044); MMP9 showed no significant result with any of the prognostic factors. No significant correlation could be detected between age and MMP9, CEA, CA19.9 and galectin3 (p -value 0.087, 0.137, 0.183 and 0.292 respectively).
The diagnostic accuracy of galectin 3 showed the highest sensitivity, followed by CEA, and then CA19.9 and lastly MMP9 (96.9%, 92.3%, 81.5% and 75.4% respectively). As regards specificity % CEA, CA19.9 and MMP9 showed 100% specificity each, while galectin 3 showed relatively lower specificity % (90.3%).
Double combination between galectin 3 and CEA showed comparable high diagnostic accuracy (94.8%) followed by CA19.9 (87.5%) then MMP9 (83.3%). The best sensitivity (98.5 %) was obtained when combining galectin 3 & CA19. 11(22) Other pathological types= 2(4%) met. Adenocarcinoma, 1(2%) met. squamous cell carcinoma, 2(4%) intramoucosal adenocarcinoma, 4(8%) mucinous adenocarcinoma, 2(4%) signet ring adenocarcinoma, 1(2%) met. signet ring adenocarcinoma, 1(2%) met. mucinous adenocarcinoma Others pathology = 2(4%) metadenocarcinoma, 1(2%) metsquamous cell carcinoma, 2(4%) intramoucosal adenocarcinoma, 4(8%) mucinous adenocarcinoma, 2(4%) signet ring adenocarcinoma, 1(2%) metsignet ring adenocarcinoma, 1(2%) metmucinous adenocarcinoma 
Matrix metalloproteinase 9 or gelatinase B is a member of matrix metalloproteinases family which is structurally related to zinc-dependent endopeptidases proteolytic enzymes that are collectively capable of degrading essentially all components of extracellular matrix including the basement membrane and type IV collagen. They are associated with tissue remodeling in normal and pathological processes characterized by excessive degradation of ECM (6) , as rheumatoid arthritis, osteoarthritis, periodontitis, autoimmune blistering disorders of the skin, they also play a role in the development, invasion and metastasis (7) of malignant tumors as colorectal (8) , gastric (9) , lung (10) , and breast cancer (11) . The aim of the present work was to evaluate the diagnostic role of galectin3 and matrix metalloproteinase9 in colon cancer patients, and to compare them with the benign colon patients group, after treatment patients group, and normal healthy control group. Serum concentrations of both markers were also compared with CEA, CA19,9 and some prognostic factors of cancer colon.
The aim of the present work was to evaluate the diagnostic role of galectin3 and matrix metalloproteinase9 in colon cancer patients, and to compare them with the benign colon patients group, after treatment patients group, and normal healthy control group. Serum concentration of both markers were also compared with CEA, CA19,9 and some prognostic factors of cancer colon.
In the present study, comparing the four studied tumor markers (CEA, CA19.9, galectin3 and MMP9) between the different groups (colon cancer before treatment, benign colon disease, colon cancer after treatment and control group), revealed statistically significant difference for all markers (p-value < 0.0001 for each).
Pair wise comparison of the studied tumor markers between the different groups revealed statistically significant differences between each pair.
In the current study, galectin 3, showed the highest results in the malignant group, followed by the benign then the control and lastly comes the after treatment group (10.2±1.24, 5.69±0.75, 36. 4.18±1.08 and 1.93±0.54 ng/ml respectively) Consistently, up to 5-fold increase of galectin-3 concentration was reported in sera of patients with colorectal cancer compared to the control group in a study by Iurisci et al. (27) . Similarly, galectin-3 levels were higher in sera of non metastatic colorectal cancer patients than in controls (p<0.0001), particularly in more differentiated tumors (p<0.04) in a study by Iacovazzi et al.
(5) .
Arfaoui-Toumi et al.
(28) as well, investigated the involvement of galectin-3 in colorectal cancer development using a comparative immunohistochemical analysis of galectin-3 expression in terms of intensity and distribution in normal mucosa, in primary tumor and in metastasis from 200 patients with colorectal cancer. They found a strong and diffuse positive staining of galectin-3 in both adjacent and distanced normal mucosa, in well differentiated adenocarcinoma and in metastasis.
In the present study, MMP9, CEA ,and CA 19.9 showed highest results in the malignant group, followed by the benign then the after treatment and lastly comes the control group . While galectin 3 showed higher results in the control group compared to the after treatment group, MMP9, CEA and CA 19.9 showed higher results in the after treatment group compared to the control group.
Consistently, the preoperative serum levels of MMP-9, TIMP-1, CEA, and CA 19-9 were significantly higher in the CRC group than in the healthy subjects in a study by Barbara et al. (29) . Also, Hurst et al (32) and confirmed by our results, she studied the MMP9 expression by immunohistochemical analysis in human colorectal cancer and the correlation of that expression with the prognostic factors. The study showed that MMP-9 was expressed in 72% (strong expression in 35% of cases). Increased levels of MMP-9 protein expression in colorectal carcinoma tissues as compared to normal tissues suggest their association with colorectal tumor invasion and metastasis.
In the present study, on comparing CEA with the different prognostic factors, the comparison was statistically significant for stage, lymph node and distant metastasis (pvalue 0.0001, 0.0001 and 0.0026 respectively), CA19.9 was statistically significant for distant metastasis, stage and pathology (p-value <.0001, 0.0041 and 0.0043 respectively). As regards MMP9, there was no significant results with the stage, grade or lymph node or distant metastasis (p-value 0.75, 0.55, 0.30 and 0.8 respectively).
In contrast to our results, many authors detected significant correlations when comparing MMP-9 to different prognostic factors, this discrepancy might be attributed to the difference in the ethnic group studied, or different techniques or sample size used, MMP-9 expression was significantly higher in patients with low-grade differentiation and distant metastasis (p = 0.003 and p = 0.005, respectively), and patients with MMP-9-positive expression had a poorer prognosis (p = 0.008) in a study by Zhang et al., (29) . Vacirca, Zucker (33) showed that the over-expression of MMP-1, -2, -3. -7, -9, -13 have been demonstrated in human colorectal cancers. The degree of over-expression of some MMPs has been noted to correlate with stage of disease and/or prognosis.
Also, Chu et al. (34) found that MMP-9 expression tended to increase from T1 to T4 (P< 0.001). Further analysis of the correlation between MMP-9 expression and node status revealed that node positive colorectal cancer samples had more MMP-9-positive expression than did nodenegative ones (P< 0.001). Regarding distant metastasis, M1 colorectal cancer samples had more positive MMP-9 staining than did M0 ones, whereas MMP-9 expression was not correlated with patient gender, age, tumor location or differentiation status.
Also, the levels of MMP-9, TIMP-1, CEA and CA 19.9 correlated with the Duke's stage and were the highest in the sera of CRC patients with stage D in a study by Barbra et al.
(29) . Similarity, a statistically significant association was found between the expression of MMP9 and lymph node metastasis in a study by Guzinska-Ustymowicz (31) . Ggalectin-3  has  pleiotropic  biological functions and has been  implicated  in  cell  growth,  differentiation, adhesion, RNA processing, apoptosis, and malignant transformation (35) . Bresalier et al., (36) reported that galectin-3 expression was correlated with colon cancer metastasis. Galectin-3 provides tumor cells with anti-apoptotic and anti anoikis activities, which are thought to be critical for anchorage-independent cell survival in the circulation that takes place during dissemination (37) . Changes in circulating galectin-3 levels in cancer patients may contribute significantly to the metastatic spread of disseminating cancer cells by enhancing their ability to adhere to blood vessel endothelium and by helping their avoidance of immune surveillance. Thus, targeting the galectin-3 actions in the circulation may hold significant promise for future development of novel therapeutic agents to prevent metastasis and reduce cancerassociated fatality (38) . In the current study, galectin3 was statistically significant for distant metastasis (p-value 0.0044); while there was no significant results when compared to other prognostic factors. Iurisci et al, (27) postulated that patients with metastatic disease have higher concentrations of circulating galectin-3 than those with localized tumors. The source of increased serum galectin-3 in cancer patients remains unknown but has been speculated to be generated by the tumor cells as well as the peri-tumoral inflammatory and stromal cells.
Similarly, there was no significant correlation between galectin-3 expression and some prognostic factors, such as age, gender, histological type, lymph node metastasis, and tumor stage, but in contrast to our results, Kaori et al., (39) found no relation between galectin3 and liver metastasis.
Endo et al . (21) demonstrated that galectin 3 was significantly related to pathological type, lymph node metastasis, and distant metastasis. Galectin-3 expression was found to be an independent prognostic factor ranking with lymph node metastasis and prognosis in his study on 121 patients with colorectal cancer.
In contrast, John et al. (37) showed that galectin-3 is efficacious in reducing metastases and tumor volumes and weights in primary tumors in a nude mouse model of human breast cancer. However, inconsistent and varying amounts of galectin-3 expression in tumors of the same origin reflect the heterogeneity of tumor cells; therefore, the existence of a correlation between galectin-3 and malignancy is unlikely.
In this study, on studying the diagnostic performance of all the studied at the chosen cutoffs, CEA (21 ng/ml), CA19.9 (58 U/ml), MMP9 (90.9 ng/ml) and galectin 3 (4.8 ng/ml), galectin 3 showed the highest sensitivity, followed by CEA, and then CA19.9 and lastly MMP9 (96.9%, 92.3%, 81.5% and 75.4% respectively).
As regards specificity % CEA, CA19.9 and MMP9 showed 100% specificity each, while galectin 3 shows relatively lower specificity % (90.3%). Galectin 3 and CEA showed comparable high diagnostic accuracy (94.8%) followed by CA19.9 (87.5%) then MMP9 (83.3%).
CEA may boast a degree of specificity for malignancy; it is also elevated in many diverse states including old age, obesity, smoking, inflammatory lung disease, liver disease, and other diseases of the digestive tract (40) . Elevations in CEA levels are also reported in noncolorectal malignancies, including lung (74%) (41) , breast (57%), esophageal, gastric, and pancreatic carcinomas. It is also more likely to be elevated in disseminated disease than in locally confined (and hence surgically curable) lesions (42) . Barbra et al.
(29) calculated the sensitivities of MMP-9 as 55%, CEA as 39%, and CA 19-9 as 11%. The diagnostic sensitivity of biomarkers tested increased with their combined use.
In this study, galectin3 had the highest sensitivity and slightly low specificity, while MMP9, CEA and CA 19.9 showed the lowest sensitivity and 100% specificity, so using the markers in combination might provide high sensitivity and specificity.
On comparing sensitivity and specificity and diagnostic accuracy for the studied tumor markers in double combinations, the best sensitivity (98.5 %) was obtained when combining galectin 3 & CA19.9 at cut offs (4.8 ng/ml -58 U/ml) respectively and galectin 3 & MMP9 at cutoffs (4.8 ng/ml -90.9ng/m) respectively.
As regards specificity, the double combination between CEA & CA19.9 at cut offs (21 ng/ml -58 U/ml) respectively and MMP9 & CA19.9 at cut offs (90.9 ng/ml -58 U /ml) respectively showed the highest specificity of 100% each, followed by CEA & MMP9 at cut offs (21 ng/ml -90.9ng/ml) respectively with specificity of 91.9%.
On studying the correlation between all the studied tumor markers, there were significant positive correlations between CEA & CA19.9 , CEA & galectin 3, CEA & MMP9, CA19.9 & Galectin 3, CA19.9 & MMP9 and MMP9 & Galectin 3 (p=0.0001) each.
The collagen-like domain of galectin-3 is susceptible to rapid and efficient cleavage by MMPs, in particular MMP-2, MMP-9, and membrane type 1-MMP resulting in the generation of a 22 kDa cleaved product (14) . This might explain the significant positive correlation found between galectin3 and MMP-9. Also, the significant positive correlation between galectin3 and CEA in the present study might be explained by the fact that galectin-3 may express its malignant potential through regulation of apoptotic signal transduction by interaction with its ligands. The ligands identified in colon cancer include mucin, Mac-2-binding protein, CEA, lamp 1 and lamp 2 glycoproteins, and haptoglobin related protein (43) . So, increase in galectin3 may be associated with increase in CEA which acts as its ligand.
Conclusion: higher concentrations of galectin3 and MMP9 in the cancer colon group compared to the benign and normal control groups which make them potential diagnostic markers for CRC. Also, being higher in the malignant group compared to the after treatment group makes them suitable for follow up of CRC patients during the course of treatment. The high sensitivity of galectin3 and high specificity of MMP9, CEA and CA19.9 encourage the use of double combinations between galectin3 and any of the former 3 markers in order to improve the diagnostic accuracy. Further studying of larger number of cases and long term follow up for the patients is recommended to support these results and to detect whether these markers could predict patients' survival or not.
